← boardnext 2027-12-31next 2028-03-08next 2028-05-01next 2029-10next 2031-02-28
PTCT
PYC Therapeuticsdistress 1/10 · well-funded / low risk$77.93-1%today-13% from 52w high
Lead: Huntington's disease
Revenue
$273M
Liquidity
$1892M
Runway
8.7 yrs
Shares 1y
-90%
Price & events
+2.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-0.8%
1W
-5.1%
1M
+13.6%
3M
+3.6%
6M
+65.5%
1Y
+132.3%
2Y
+89.1%
5Y
+28.8%
All
Overview
- Market Cap
- $646.42M
- Enterprise Value
- $98.45M
- Volume
- 40.65K
- 52 Week Range
- $43.30 – $89.55
- Total Shares
- 8.29M
- Float Shares
- 73.17M
- Short %
- 28.36%
- % Held by Insiders
- 7.38%
- % Held by Institutions
- 117.59%
- RVOL
- 0.02x
- Beta
- 0.53
Pipeline stages · 6 programs
Vatiquinone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VP-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
UCL70805F
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PYC-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sepiapterin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PTC923
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12-31 Estimated 50% readout ~2028-03-15 | Phase 3 | Vatiquinonepriority review | Friedreich Ataxia | — | active not recruiting |
| 2028-03-08 Estimated 50% readout ~2028-04-22 | Phase 1/2 | VP-001 | Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies | — | active not recruiting |
| 2028-05-01 Estimated 50% readout ~2028-05-31 | Phase 1 | UCL70805F | CD70-positive Advanced Renal Clear Cell Carcinoma | — | not yet recruiting |
| 2029-03-15 Estimated 50% readout ~2029-05-29 | Phase 3 | Vatiquinonepriority review | Friedreich's Ataxia | — | not yet recruiting |
| 2029-10 Estimated 50% readout ~2029-11-15 | Phase 1/2 | PYC-001 | OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy, Hereditary Optic Atrophies, Kjer Optic Atrophy | — | recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2031-02-28 Estimated 50% readout ~2031-05-14 | Phase 3 | Sepiapterin | Phenylketonuria | — | recruiting |
| 2026-06-30 | Phase 3 | PTC923 | Phenylketonuria | — | active not recruiting |
| 2025-04-15 | Phase 3 | Vatiquinonepriority review | Inherited Mitochondrial Disease | 101 | completed |
Catalyst news & presentations · 17
- Q3 2026Guided 70%trial initiationsecondaryPhase 3vatiquinone · Initiation of open-label registration study with matched natural history control based on FDA feedback.SEC 8-K
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026trial initiationsecondaryPhase 3votoplam · First patient dosed in global Phase 3 INVEST-HD study.SEC 8-K
- April 2026readoutvotoplam · 24-month interim analysis of PIVOT-HD extension study showed dose-dependent benefit on cUHDRS.SEC 8-K
- 2026-02-12withdrawalTranslarna (ataluren) · Withdrew NDA resubmission for nonsense mutation DMD after FDA feedback.SEC 8-K
- January 12, 2026conferencedata presentationsecondaryCorporate update at 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
- Q4 2025regulatory submissionFiled (NDA/BLA)sepiapterin · Japan regulatory decision expected for SephienceSEC 8-K
- Tuesday, December 2ndconferencedata presentationsecondaryR&D Day in New YorkSEC 8-K
- 2025-08-19crlvatiquinone · FDA issued CRL for vatiquinone NDA for Friedreich's ataxia; additional study needed.SEC 8-K
- August 19, 2025PDUFAPDUFAvatiquinone · PDUFA action date for vatiquinone NDASEC 8-K
- July 2025PDUFAPDUFAsepiapterin · U.S. approval decision expected for sepiapterin for PKU.SEC 8-K
- expected in Q2 2025chmp opinionCHMP (EU)sepiapterin · CHMP opinion on sepiapterin MAA expectedSEC 8-K
- expected in Q2 2025readoutPhase 2PTC518 · 12-month results from PIVOT-HD Phase 2 studySEC 8-K
- 2025-04-25fda agreementsepiapterin · Positive CHMP opinion for Sephience MAA in PKUSEC 8-K
- first quarter of 2025regulatory submissionFiled (NDA/BLA)PTC518 · Effective date of Novartis license agreementSEC 8-K
- 2025-03-28withdrawalTranslarna (ataluren) · European Commission adopted CHMP negative opinion and decided not to renew conditional marketing authorization for Translarna in the European Economic Area for nonsense mutation Duchenne muscular dystrophySEC 8-K
- 2024-11-27partnershipPTC518 · License and collaboration with Novartis for PTC518; $1B upfront plus milestonesSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $96 (+23% upside) · 14 analysts
- 2026-07-20Wells FargoOverweight
- 2026-07-16Cantor FitzgeraldOverweight
- 2026-07-07RBC CapitalSector Perform
- 2026-05-27JefferiesHold → Buy
- 2026-05-08Wells FargoOverweight
- 2026-05-08TD CowenHold → Buy
Competitors — Huntington's disease
Recent news
- 2026-07-20Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
- 2026-07-20PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
- 2026-07-20PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
- 2026-07-19Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518? - Sahm
- 2026-07-16Insider Sale: CHIEF FINANCIAL OFFICER of $PTCT Sells 3,494 Shares - Quiver Quantitative
- 2026-07-16PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes - Stock Titan
- 2026-07-16PTCT Maintained by Cantor Fitzgerald - Price Target Raised to $1 - GuruFocus
- 2026-07-16PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities - The Globe and Mail
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.